AusperBio
Develops oligonucleotide therapeutics targeting chronic hepatitis B
$120MSeries C
Role not disclosedActivity from announced rounds
Develops oligonucleotide therapeutics targeting chronic hepatitis B
Developing the next generation of precision medicines by going beyond genomics.